Online inquiry

IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13622MR)

This product GTTS-WQ13622MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF4 gene. The antibody can be applied in Allergic asthma, Allergic rhinitis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001297562.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7292
UniProt ID P23510
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13622MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8249MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ7887MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ6508MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ14123MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aPCSK927
GTTS-WQ3707MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ13904MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ1998MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ2410MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 110
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW